Your browser doesn't support javascript.
loading
Type 1 diabetes and inborn errors of immunity: Complete strangers or 2 sides of the same coin?
Mancuso, Gaia; Bechi Genzano, Camillo; Fierabracci, Alessandra; Fousteri, Georgia.
Afiliação
  • Mancuso G; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Bechi Genzano C; Columbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
  • Fierabracci A; Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Fousteri G; Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: fousteri.georgia@hsr.it.
J Allergy Clin Immunol ; 151(6): 1429-1447, 2023 06.
Article em En | MEDLINE | ID: mdl-37097271
Type 1 diabetes (T1D) is a polygenic disease and does not follow a mendelian pattern. Inborn errors of immunity (IEIs), on the other hand, are caused by damaging germline variants, suggesting that T1D and IEIs have nothing in common. Some IEIs, resulting from mutations in genes regulating regulatory T-cell homeostasis, are associated with elevated incidence of T1D. The genetic spectrum of IEIs is gradually being unraveled; consequently, molecular pathways underlying human monogenic autoimmunity are being identified. There is an appreciable overlap between some of these pathways and the genetic variants that determine T1D susceptibility, suggesting that after all, IEI and T1D are 2 sides of the same coin. The study of monogenic IEIs with a variable incidence of T1D has the potential to provide crucial insights into the mechanisms leading to T1D. These insights contribute to the definition of T1D endotypes and explain disease heterogeneity. In this review, we discuss the interconnected pathogenic pathways of autoimmunity, ß-cell function, and primary immunodeficiency. We also examine the role of environmental factors in disease penetrance as well as the circumstantial evidence of IEI drugs in preventing and curing T1D in individuals with IEIs, suggesting the repositioning of these drugs also for T1D therapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article